ArticleScientific reports2026
Harnessing the potential of selected Himalayan species for phyto-cosmeceutical formulations guided through biochemometric analysis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study aimed to biochemometrically guide the identification of nine selected Himalayan species with potential anti-ageing and bioactivity properties. The results demonstrated that the majority of the species exhibited strong UV shielding capabilities, particularly within the UV-C (180-280 nm) and UV-B (280-315 nm) spectral regions. In-vitro sun protection factor (SPF) assessment of the extract at 500 μg/mL revealed a comparable SPF value to that of the reference compound, epigallocatechin gallate (positive control). Notably, Berberis aristata exhibited the highest tyrosinase inhibitory activity (55.15 ± 0.99%) compared to the standard epigallocatechin gallate (48.14 ± 1.94%) at a fixed concentration (1.25 mg/ mL). Conversely, anti-hyaluronidase activity was higher in the positive control, epigallocatechin gallate (55.99 ± 0.54%), than in B. aristata (38.05 ± 0.15%). Antioxidant potential, as evaluated by free radical scavenging assays, indicated that the extracts of B. aristata, Rubus ellipticus, and Ficus auriculata demonstrated strong radical scavenging potential. Moreover, all the tested species, except for F. auriculata, exhibited over 50% protection against DNA damage, with Morus alba (74.55%), Thalictrum foliolosum (73.57%), and Tinospora cordifolia (68.50%) demonstrating the most significant protective activity. HPLC-PDA analysis revealed a total of thirteen bioactive compounds, with ascorbic acid and gallic acid being consistently detected across the studied species. Lastly, multivariate chemometric analysis identified B. aristata and F. auriculata as promising species, demonstrating synergistic DNA protective and significant inhibition of extracellular matrix-degrading enzymes, suggesting potential for phyto-cosmeceutical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.